Importance of Glycemic Control in Cancer Patients with Diabetes: Treatment through End of Life.
Importance of Glycemic Control in Cancer Patients with Diabetes: Treatment through End of Life.
复制标题
DOI：
10.4103/apjon.apjon_40_17
复制
发表时间：
2017-10
影响因子：
1.8
通讯作者：
Hershey DS
中科院分区：
文献类型：
--
作者：
Hershey DS
患有糖尿病的癌症患者发生感染、住院和需要减少或停止化疗的风险增加。虽然已经假设血糖控制会增加这些不良事件的风险，但很少有研究探讨这一假设。本文的目的是讨论糖尿病和癌症患者在治疗期间至生命结束期间血糖控制的重要性。发现血糖控制发挥作用;癌症和糖尿病患者所经历的健康相关生活质量的总体水平，所经历的症状严重程度，并可能影响个体的总体生存期。还需要制定循证政策和实践指南，以帮助临床医生在护理的各个阶段管理这些患者。利用糖尿病教育者和先进的实践，护士提供管理和护理协调服务需要考虑。幸存者护理计划应同时解决癌症和糖尿病管理问题。最后，血糖控制应持续到生命结束，主要目标是避免低血糖事件。
Cancer patients with diabetes are at increased risk for developing infections, being hospitalized, and requiring chemotherapy reductions or stoppages. While it has been hypothesized that glycemic control increases the risk for these adverse events, few studies have explored this hypothesis. The purpose of this paper is to discuss the importance of glycemic control in patients with diabetes and cancer during treatment through end of life. Glycemic control was found to play a role; the overall level of health-related quality of life experienced by patients with cancer and diabetes, level of symptom severity experienced and can impact the overall survival of the individual. Evidence-based policies and practice guidelines also need to be developed to help clinicians manage these patients during all phases of care. Using diabetes educators and advance practice, nurses to provide management and care coordination services need to be considered. Survivorship care plans should address both cancer and diabetes management. Finally, glycemic control should continue through end of life, with the main goal of avoiding hypoglycemic events.